The drug giant has undertaken a viability study, which will be completed by December.
Under consideration are the bulk drugs unit in Mysore and the formulations unit in Bangalore. The Bangalore unit also makes Iodex, which is marketed by Glaxo SmithKline Consumer Healthcare.
Confirming the development, a senior executive at Glaxo SmithKline told Business Standard:
